Merck & Co., Inc. (NYSE:MRK) Receives $131.25 Average Price Target from Brokerages

Merck & Co., Inc. (NYSE:MRKGet Free Report) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $131.25.

A number of equities research analysts have commented on the stock. UBS Group lifted their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Berenberg Bank lifted their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Barclays lifted their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Truist Financial reiterated a “buy” rating and set a $142.00 price target (up previously from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, April 18th.

Get Our Latest Research Report on MRK

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $126.94 on Friday. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The company has a 50 day simple moving average of $126.24 and a two-hundred day simple moving average of $115.51. The company has a market capitalization of $321.54 billion, a price-to-earnings ratio of 906.71, a P/E/G ratio of 1.63 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The business had revenue of $14.63 billion during the quarter, compared to the consensus estimate of $14.49 billion. During the same quarter last year, the firm earned $1.62 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Analysts expect that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the sale, the insider now directly owns 19,569 shares in the company, valued at approximately $2,443,972.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

Institutional investors have recently bought and sold shares of the stock. Kennedy Investment Group increased its holdings in shares of Merck & Co., Inc. by 16.0% during the 4th quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock valued at $280,000 after purchasing an additional 354 shares in the last quarter. Schear Investment Advisers LLC boosted its position in shares of Merck & Co., Inc. by 16.0% during the 4th quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock valued at $352,000 after acquiring an additional 445 shares during the last quarter. Constitution Capital LLC boosted its position in shares of Merck & Co., Inc. by 5.9% during the 4th quarter. Constitution Capital LLC now owns 3,600 shares of the company’s stock valued at $392,000 after acquiring an additional 200 shares during the last quarter. Harbour Trust & Investment Management Co acquired a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $599,000. Finally, Mosaic Family Wealth Partners LLC increased its stake in Merck & Co., Inc. by 4.0% during the fourth quarter. Mosaic Family Wealth Partners LLC now owns 2,995 shares of the company’s stock worth $327,000 after purchasing an additional 116 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

(Get Free Report

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.